Neuroprotective herbs and foods from different traditional medicines and diets

Molecules

Volumn 15, Issue 5, 2010, Pages 3517-3555

  Iriti, Marcello ^a,b   Vitalini, Sara ^a   Fico, Gelsomina ^a   Faoro, Franco ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b CNR   (Italy)

Author keywords

Ayurvedic medicine; Mediterranean diet; Neurodegenerative diseases; Nutritional therapy; Phytotherapy; Traditional Chinese medicine

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTIOXIDANT; NEUROPROTECTIVE AGENT;

DIET; FOOD; HUMAN; MEDICINAL PLANT; METHODOLOGY; REVIEW; TRADITIONAL MEDICINE; PROCEDURES;

ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; DIET; FOOD; HUMANS; MEDICINE, TRADITIONAL; NEUROPROTECTIVE AGENTS; PLANTS, MEDICINAL;

EID: 77952802551     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules15053517     Document Type: Review

References (249)

1. Suk, K. Regulation of neuroinflammation by herbal medicine and its implications for neurodegenerative diseases. A focus on traditional medicines and flavonoids. Neurosignals 2005, 14, 23-33.
2. Adams, M.; Gmünder, F.; Hamburger, M. Plants traditionally used in age related brain disorders-a survey of ethnobotanical literature. J. Ethnopharmacol. 2007, 113, 363-381.
3. McClatchey, W.C.; Mahady, G.; Bennett, B.C.; Shiels, L.; Savo, V. Ethnobotany as a pharmacological research tool and recent developments in CNS-active natural products from ethnobotanical sources. Pharmacol. Therapeut. 2009, 12, 239-254.
4. Ho, Y.S.; So, K.F.; Chang, R.C.C. Anti-aging herbal medicine-how and why can they be used in aging-associated neurodegenerative diseases? Ageing Res. Rev. 2010, doi: 10.1016/j.arr.2009.10.001.
5. Esposito, E.; Rotilio, D.; Di Matteo, V.; Di Giulio, C.; Cacchio, M.; Algeri, S. A review of specific dietary antioxidants and the effects on biochemical mechanisms related to neurodegenerative processes. Neurobiol. Aging 2002, 23,719-735.
6. Aruoma, O.I.; Bahorun, T.; Jen, L.S. Neuroprotection by bioactive components in medicinal and food plant extracts. Rev. Mutat. Res. 2003, 544, 203-215.
7. Ferrari, C.K.B. Functional foods, herbs and neutraceuticals: towards biochemical mechanisms of healthy aging. Biogerontology 2004, 5, 275-289.
8. Zhao, J. Nutraceuticals, nutritional therapy, phytonutrients and phytotherapy for improvement of human health: a perspective on plant biotechnology application. Rec. Pat. Biotech. 2007, 1, 75-97.
9. 9. Lee, J.; Koo, N.; Min, D.B. Reactive oxygen species, aging, and antioxidant nutraceuticals. Compr. Rev. Food Sci. Food Saf. 2004, 3, 21-33.
10. Halliewll, B. Reactive oxygen species and central nervous systems. J. Neurochem. 1992, 59, 1609-1623.
11. Floyd, R.A. Antioxidants, oxidative stress and degenerative neurological disorders. Proc. Soc. Exp. Biol. Med. 1999, 222, 236-245.
12. Barja, G. Free radicals and aging. Trends Neurosci. 2004, 23, 209-216.
13. Smith, K.J.; Kapoor, R.; Felts, P.A. Demyelination: the role of reactive oxygen and nitrogen species. Brain Pathol. 1999, 9, 69-92.
14. Yu, B.P. Cellular defenses against damage from reactive oxygen species. Physiol. Rev. 1994, 74, 139-162.
15. Cao, G.; Sofic, E.; Prior, R.L. Antioxidant and prooxidant behavior of flavonoids: structure-activity relationships. Free Rad. Biol. Med. 1997, 22, 749-760.
16. Prior, R.L; Cao, G. Antioxidant phytochemicals in fruits and vegetables: diet and health implications. Hortic. Sci. 2000, 35, 588-592.
17. Vinson, J.A.; Yang, J.; Proch, J.; Liang, X. Grape juice, but not orange juice, has in vitro, ex vivo, and in vivo antioxidant properties. J. Med. Food 2000, 3, 167-171.
18. Vinson, J.A.; Teufel, K.; Wu, N. Red wine, dealcoholized red wine, and especially grape juice, inhibit atherosclerosis in a hamster model. Atherosclerosis 2001, 156, 67-72.
19. Bors, W.; Heller, W.; Michel, C.; Saran, M. Flavonoids as antioxidants: determination of radical-scavenging efficiencies. Methods Enzymol. 1990, 186, 343-355.
20. Bors, W.; Michel, C.; Stettmaier, K. Antioxidant effects of flavonoids. Biofactors 1997, 6, 399-402.
21. Pillon, B.; Deweer, B.; Agid, Y.; Dubois, B. Explicit memory in Alzheimer's, Huntington's, and Parkinson's diseases. Arch. Neurol. 1993, 50, 374-379.
22. Paolo, A.M.; Tröster, A.I.; Glatt, S.L.; Hubble, J.P.; Koller, W.C. Differentiation of the dementias of Alzheimer's and Parkinson's disease with the dementia rating scale. J. Geriatr. Psychiatry Neurol. 1995, 8, 184-188.
23. Menken, M.; Munsat, T.L.; Toole, J.F. The global burden of disease study: implications for neurology. Arch. Neurol. 2000, 57, 418-420.
24. Brookmeyer, R.; Gray, S.; Kawas, C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am. J. Public Health 1998, 88, 1337-1342.
25. Hebert, L.E.; Scherr, P.A.; Bienias, J.L.; Bennett, D.A.; Evans, D.A. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch. Neurol. 2003, 60, 1119-1122.
26. Murray, C.J.L.; Lopez, A.D. The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries, and Risk Factors in 1990 and Projected To 2020; Harvard University Press: Cambridge, USA, 1996.
27. Rocca, W.A.; Hofman, A.; Brayne, C.; Breteler, M.M.B.; Clarke, M.; Copeland, J.R.M.; Dartigues, J.F.; Engedal, K.; Hagnell, O.; Heeren, T.J.; Jonker, C.; Lindesay, J.; Lobo, A.; Mann, A.H.; Mölsä, P.K.; Morgan, K.; O'Connor, D.W.; da Silva Droux, A.; Sulkava, R.; Kay, D.W.K.; Amaducci, L. for the EURODEM-Prevalence Research Group. Frequency and distribution of Alzheimer's disease in Europe: a collaborative study of 1980-1990 prevalence findings. Ann. Neurol. 1991, 30, 381-390.
28. Tanner, C.M.; Goldman, S.M. Epidemiology of Parkinson's disease. Neurol. Clin. 1996, 14, 317-335.
29. Elbaz, A.; Bower, J.H.; Maraganore, D.M.; McDonnell S.K.; Peterson, B.J.; Ahlskog, J.E.; Schaid, D.J.; Rocca, W. A risk tables for parkinsonism and Parkinson's disease. J. Clin. Epidemiol. 2002, 55, 25-31.
30. Dorsey, E.R.; Constantinescu, R.; Thompson, J.P.; Biglan, K.M.; Holloway, R.G.; Kieburtz, K.; Marshall, F.J.; Ravina, B.M.; Schifitto, G.; Siderowf, A.; Tanner, C.M. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007, 68, 384-386.
31. Zhang, Z.X.; Roman, G.C. Worldwide occurrence of Parkinson's disease: an updated review. Neuroepidemiology 1993, 12, 195-208.
32. Emard, J.F.; Thouez, J.P.; Gavreau, D. Neurodegenerative diseases and risk factors: a literature review. Soc. Sci. Med. 1995, 40, 847-858.
33. Shastry, B.S. Neurodegenerative disorders of protein aggregation. Neurochem. Int. 2003, 43, 1-7.
34. Selkoe, D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 2001, 81, 741-766.
35. Agorogiannis, E.I.; Agorogiannis, G.I.; Papadimitriou, A.; Hadjigeorgiou, G.M. Protein misfolding in neurodegenerative diseases. Neuropathol. Appl. Neurobiol. 2004, 30, 215-224.
36. Mayeux, R. Epidemiology of neurodegeneration. Annu. Rev. Neurosci. 2003, 26, 81-104.
37. Elbaz, A.; Dufouil, C.; Alpérovitch, A. Interaction between genes and environment in neurodegenerative diseases. Compte. Rendus Biol. 2007, 330, 318-328.
38. Hunot, S.; Boissiere, F.; Faucheux, B.; Brugg, B.; Mouatt-Prigent, A.; Agid, Y.; Hirsch, E.C. Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. Neuroscience 1996, 72, 355-363.
39. Perry, G.; Taddeo, M.A.; Nunomura, A.; Zhu, X.; Zenteno-Savin, T.; Drew, K.L.; Shimohama, S.; Avila, J.; Castellani, R.J.; Smith, M.A. Comparative biology and pathology of oxidative stress in Alzheimer and other neurodegenerative diseases: beyond damage and response. Comp. Biochem. Physiol. C Toxicol. Pharmacol. 2002, 133, 507-513.
40. Jenner, P. Oxidative stress in Parkinson's disease. Ann. Neurol. 2003, 53, S26-S38.
41. Nikam, S.; Nikam, P.; Ahaley, S.K.; Sontakke, A.V. Oxidative stress in Parkinson's disease.Indian J. Clin. Biochem. 2009, 24, 98-101.
42. Nikam, S.; Nikam, P.; Ahaley, S.K. Role of free radical and antioxidant imbalance in pathogenesis of Parkinson's disease. Biomed. Res. 2009, 20, 55-58.
43. Kaltschmidt, B.; Uherek, M.; Volk, B.; Baeuerle, P.A.; Kaltschmidt, C. Transcription factor NF-kB is activated in primary neurons by amyloid B peptides and in neurons surrounding early plaques from patients with Alzheimer's disease. Proc. Natl. Acad. Sci. USA 1997, 94, 2642-2647.
44. Kaltschmidt, B.; Uherek, M.; Wellmann, H.; Volk, B.; Kaltschmidt, C. Inhibition of NF-kB potentiates amyloid β-mediated neuronal apoptosis. Proc. Natl. Acad. Sci. USA 1999, 96, 9409-9414.
45. Kaltschmidt, B.; Heinrich, M.; Kaltschmidt, C. Stimulus-dependent activation of NF-kappaB specifies apoptosis or neuroprotection in cerebellar granule cells. Neuromol. Med. 2002, 2, 299-309.
46. Huang, X.; Atwood, C.S.; Hartshorn, M.A.; Multhaup, G.; Goldstein, L.E.; Scarpa, R.C.; Cuajungco, M.P.; Gray, D.N.; Lim, J.; Moir, R.D.; Tanzi, R.E.; Bush, A.I. The Aβ peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry 1999, 35, 7609-7616. (Pubitemid 29289332)
47. Huang, X.; Moir, R.D.; Tanzi, R.E.; Bush, A.I.; Rogers, J.T. Redox-active metals, oxidative stress, and Alzheimer's disease pathology. Ann. NY Acad. Sci. 2004, 1012, 153-163.
48. Zhu, X.; Smith, M.A.; Perry, G.; Aliev, G. Mitochondrial failures in Alzheimer's disease. Am. J. Alzheimers Dis. Other Demen. 2004, 19, 345-352.
49. Jenner, P. Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease. Neurology 2004, 63, S13-S22.
50. Yuan, H.; Zheng, J.C.; Liu, P.; Zhang, S.F.; Xu, J.Y.; Bai, L.M. Pathogenesis of Parkinson's disease: oxidative stress, environmental impact factors and inflammatory processes. Neurosci. Bull. 2007, 23, 125-130.
51. Klafki, H.W.; Staufenbiel, M.; Kornhuber, J.; Wiltfang, J. Therapeutic approaches to Alzheimer's disease. Brain 2006, 129, 2840-2855.
52. Persson, C.M.; Wallin, A.K.; Levander, S.; Minthon, L. Changes in cognitive domains during three years in patients with Alzheimer's disease treated with donepezil. BMC Neurol. 2009, 9, 7.
53. Tariot, P.N.; Farlow, M.R.; Grossberg, G.T.; Graham, S.M.; McDonald S.; Gergel, I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004, 291, 317-324.
54. Lleo, A.; Greenberg, S.M.; Growdon, J.H. Current pharmacotherapy for Alzheimer's disease. Annu. Rev. Med. 2006, 57, 513-533.
55. Moore, A.H.; O'Banion, M.K. Neuroinflammation and anti-inflammatory therapy for Alzheimer's disease. Adv. DrugDeliv. Rev. 2002, 54, 1627-1656.
56. Tariot, P.N.; Federoff, H.J. Current treatment for Alzheimer disease and future prospects. Alzheimer Dis. Assoc. Disord. 2003, 17, S105-S113.
57. Lewitt, P.A. Levodopa for the treatment of Parkinson's disease. N. Engl. J. Med. 2008, 359, 2468-2476.
58. Olanow, C.W.; Stern, M.B.; Sethi, K. The scientific and clinical basis for the treatment of Parkinson disease. Neurology 2009, 72, S1-S136.
59. Ginsberg, M.D. Adventures in the pathophysiology of brain ischemia: penumbra, gene expression, neuroprotection: the 2002 Thomas Willis lecture. Stroke 2003, 34, 214-223.
60. Hachinski, V. Stroke and vascular cognitive impairment: a transcisciplinary, translational and transactional approach. Stroke 2007, 35, 1396-1403.
61. Donnan, G.A.; Fisher, M.; Macleod, M.; Davis, S.M. Stroke. Lancet 2008, 371, 1612-1623.
62. Tatemichi, T.K.; Paik, M.; Bagiella, E.; Desmond, D.W.; Stern, Y.; Sano, M.; Hauser, W.A.; Mayeux, R. Risk of dementia after stroke in a hospitalized cohort: results of a longitudinal study. Neurology 1994, 44, 1885-1891.
63. Tatemichi, T.K.; Desmond, D.W.; Stern, Y.; Paik, M.; Sano, M.; Bagiella, E. Cognitive impairment after stroke: frequency, patterns, and relationship to functional abilities. J. Neurol. Neurosurg. Psychiatry 1994, 57, 202-207.
64. Jendroska, K.; Poewe, W.; Daniel, S.E.; Pluess, J.; Iwerssen-Schmidt, H.; Paulsen, J.; Barthel, S.; Schelosky, L.; Cervos-Navarro, J.; DeArmond, S.J. Ischemic stress induces deposition of amyloid beta immunoreactivity in human brain. Acta Neuropathol. 1995, 90, 461-466.
65. But, P.P.H.; Hu, S.Y.; Kong, Y.C. Vascular plants used in Chinese medicine. Fitoterapia 1980, 3, 245-264.
66. Ody, P. Practical Chinese Medicine: Understanding the Principles and Practice of Traditional Chinese Medicine and Making Them Work for You; Godsfield Press: London, UK, 2000.
67. Ou B.; Huang D.; Hampsch-Woodill, M.; Flanagan, J.A. When east meets west: the relationship between yin-yang and antioxidation-oxidation.FASEB J. 2003, 17, 127-129.
68. 68. Wu, L.; Wu, Q.; Wang, B. Yellow Emperor's canon of internal medicine. Zhongguo ke xue ji shu chu ban she : location?1997; pp. 7-8.
69. Zheng, B.C. Shennong's herbal--one of the world's earliest pharmacopoeia. J. Tradit. Chin. Med. 1985, 5, 236.
70. Jiang, W.Y. Therapeutic wisdom in traditional Chinese medicine: a perspective from modern science. Trends Pharmacol. Sci. 2005, 26, 558-563.
71. Zhou, Z.Y.; Zheng, S.L. The missing link of Ginkgo evolution. Nature 2003, 423, 821-822.
72. Fu L.M.; Li, J.T. A systematic review of single Chinese herbs for Alzheimer's disease treatment. Evid.-Based Complement. Altern.Med. 2009, doi:10.1093/ecam/nep136.
73. Wagner, H. Phytomedicine research in Germany. Environ. Health Perspect. 1999, 107, 779-781.
74. Birks J.; Grimley, E.J. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst. Rev. 2009, CD003120
75. Smith, P.F.; Maclennan, K.; Darlington, C.L. The neuroprotective properties of the Ginkgo biloba leaf: a review of the possible relationship to platelet-activating factor (PAF). J. Ethnopharmacol. 1996, 50, 131-139.
76. Chandrasekaran, K.; Mehrabian, Z.; Spinnewyn, B.; Chinopoulos, C.; Drieu, K.; Fiskum, G. Neuroprotective effects of bilobalide, a component of Ginkgo biloba extract (EGb 761) in global brain ischemia and in excitotoxicity-induced neuronal death. Pharmacopsychiatry 2003, 36, S89-S94.
77. Bastianetto, S.; Ramassamy, C.; Doré, S.; Christen, Y.; Poirier, J.; Quirion, R. The ginkgo biloba extract (EGb 761) protects hippocampal neurons against cell death induced by β-amyloid. Eur. J. Neurosci. 2000, 12, 1882-1890.
78. DeFeudis, F.V.; Drieu, K. Ginkgo Biloba extract (EGb 761) and CNS functions basic studies and clinical applications. Curr. Drug Targets 2000, 1, 25-58.
79. Yao, Z.; Drieu, K.; Papadopoulos, V. The Ginkgo biloba extract EGb761 rescues the PC12 neuronal cells from beta-amyloid-induced cell death by inhibiting the formation of beta-amyloid-derived diffusible neurotoxic ligands. Brain Res. 2001, 889, 181-190.
80. Gohil, K.; Packer, L. Global gene expression analysis identifies cell and tissue specific actions of Ginkgo biloba extract, EGb 761. Cell. Mol. Biol. 2002, 48, 625-631.
81. Luo, Y.; Smith, J.; Paramasivam, V.; Burdick, A.; Curry, K.; Buford, J.; Khan, I.; Netzer, W.; Xu, H.; Butko, P. Inhibition of amyloid-β aggregation and caspase-3 activation by the Ginkgo biloba extract EGb761. Proc. Natl. Acad. Sci. USA 2002, 99, 12197-12202.
82. Mazza, M.; Capuano, A.; Bria, P.; Mazza, S. Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer's dementia in a randomized placebo-controlled double-blind study. Eur. J. Neurol. 2006, 13, 981-985.
83. Oken, B.S.; Storzbach, D.M.; Kaye, J.A. The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease. Arch. Neurol. 1998, 55, 1409-1415.
84. Andrieu, S.; Gillette, S.; Amouyal, K.; Nourhashemi, F.; Reynish, E.; Ousset, P.J.; Albarede, J.L.; Vellas, B.; Grandjean, H. Association of Alzheimer's disease onset with Ginkgo biloba and other symptomatic cognitive treatments in a population of women aged 75 years and older from the EPIDOS study. J. Gerontol. A Biol. Sci. Med. Sci. 2003, 55, 372-377.
85. DeKosky, S.T.; Fitzpatrick, A.; Ives, D.G.; Saxton, J.; Williamson, J.; Lopez, O.L.; Burke, G.; Fried, L.; Kuller, L.H.; Robbins, J.; Tracy, R.; Woolard, N.; Dunn, L.; Kronmal, R.; Nahin, R.; Furberg, C. The Ginkgo Evaluation of Memory (GEM) study: design and baseline data of a randomized trial of Ginkgo biloba extract in prevention of dementia. Contemp. Clin. Trials 2006, 27, 238-253.
86. Fitzpatrick, A.L.; Fried, L.P.; Williamson, J.; Crowley, P.; Posey, D.; Kwong, L.; Bonk, J.; Moyer, R.; Chabot, J.; Kidoguchi, L.; Furberg, C.D.; DeKosky, S.T. Recruitment of the elderly into a pharmacologic prevention trial: the Ginkgo evaluation of memory study experience. Contemp. Clin. Trials 2006, 27, 541-553.
87. Vellas, B.; Andrieu, S.; Ousset, P.J.; Ouzid, M.; Mathiex-Fortunet, H. The GuidAge study. Methodological issues. A 5-year double-blind randomized trial of the efficacy of EGb 761® for prevention of Alzheimer disease in patients over 70 with a memory complaint. Neurology 2006, 67, S6-S11.
88. Nocerino, E.; Amato, M.; Izzo, A.A. The aphrodisiac and adaptogenic properties of ginseng. Fitoterapia 2000, 71, S1-S5.
89. Yun, T.K. Brief introduction of Panax ginseng C.A. Meyer. J. Korean Med. Sci. 2001, 16, S3-S5.
90. Tawab, M.A.; Bahr, U.; Karas, M.; Wurglics, M.; Schubert-Zsilavecz, M. Degradation of ginsenosides in humans after oral administration. Drug Metab. Dispos. 2003, 31, 1065-1071.
91. Radad, K.; Gille, G.; Liu, L.; Rausch, W.D. Use of ginseng in medicine with emphasis on neurodegenerative disorders. J. Pharmacol. Sci. 2006, 100, 175-186.
92. Rausch, W.D.; Liu, S.; Gille, G.; Radad, K. Neuroprotective effects of ginsenosides. Acta Neurobiol. Exp. 2006, 66, 369-375.
93. Joo, S.S.; Lee, D.I. Potential effects of microglial activation induced by ginsenoside Rg3 in rat primary culture: enhancement of type a macrophage scavenger receptor expression. Arch. Pharm. Res. 2005, 25, 1164-1169.
94. Chen, F.; Eckman, E.A.; Eckman, C.B. Reductions in levels of the Alzheimer's amyloid β peptide after oral administration of ginsenosides. FASEB J. 2006, 20, 1269-1271.
95. Li, N.; Liu, B.; Dluzen, D.E.; Jin, Y. Protective effects of ginsenoside Rg2 against glutamate-induced neurotoxicity in PC12 cells. J. Ethnopharmacol. 2007, 111, 458-463.
96. Joo, S.S.; Yoo, Y.M.; Ahn, B.W.; Nam, S.Y.; Kim, Y.B.; Hwang, K.W.; Lee, D.I. Prevention of inflammation-mediated neurotoxicity by Rg3 and its role in microglial activation. Biol. Pharm. Bull., 2008, 31, 1392-1396.
97. Shieh, P.C.; Tsao, C.W.; Li, J.S.; Wu, H.T.; Wen, Y.J.; Kou, D.H.; Cheng, J.T. Role of pituitary adenylate cyclase-activating polypeptide (PACAP) in the action of ginsenoside Rh2 against beta-amyloid-induced inhibition of rat brain astrocytes. Neurosci. Lett. 2008, 434, 1-5.
98. Heo, J.H.; Lee, S.T.; Chu, K.; Oh, M.J.; Park, H.J.; Shim, J.Y.; Kim, M. An open-label trial of Korean red ginseng as an adjuvant treatment for cognitive impairment in patients with Alzheimer's disease. Eur. J. Neurol. 2008, 15, 865-868.
99. Van Kampen, J.; Robertson, H.; Hagg, T.; Drobitch, R. Neuroprotective actions of the ginseng extract G115 in two rodent models of Parkinson's disease. Exp. Neurol. 2003, 154, 521-529.
100. Chen, X.C.; Zhou, Y.C.; Chen, Y.; Zhu, Y.G.; Fang, F.; Chen, L.M. Ginsenoside Rg1 reduces MPTP-induced substantia nigra neuron loss by suppressing oxidative stress. Acta Pharmacol. Sin. 2005, 26, 56-62.
101. Wang, J.; Xu, H.M.; Yang, H.D.; Du, X.X.; Jiang, H.; Xie, J.X. Rg1 reduces nigral iron levels of MPTP-treated C57BL6 mice by regulating certain iron transport proteins. Neurochem. Int. 2009, 54, 43-48.
102. Rudakewich, M.; Ba, F.; Benishin, C.G. Neurotrophic and neuroprotective actions of ginsenoside Rb1 and Rg1. Planta Med. 2001, 67, 533-537.
103. +-affected mesencephalic dopaminergic cells. J. Neural. Transm. 2004, 111, 37-45.
104. Wakabayashi, I.; Yasui, K. Wogonin inhibits inducible prostaglandin E2 production in macrophages. Eur. J. Pharmacol. 2000, 406, 477-481.
105. Park, B.K.; Heo, M.Y.; Park, H.; Kim, H.P. Inhibition of TPA-induced cyclooxygenase-2 expression and skin inflammation in mice by wogonin, a plant flavone from Scutellaria radix. Eur. J. Pharmacol. 2001, 425, 153-157.
106. Nakamura, N.; Hayasaka, S.; Zhang, X.Y.; Nagaki, Y.; Matsumoto, M.; Hayasaka, Y.; Terasawa, K. Effects of baicalein, baicalin, and wogonin on interleukin-6 and interleukin-8 expression, and nuclear factor-kb binding activities induced by interleukin-1beta in human retinal pigment epithelial cell line. Exp. Eye Res. 2003, 77, 195-202.
107. Suk, K.; Lee, H.; Kang, S.S.; Cho, G.J.; Choi, W.S. Flavonoid baicalein attenuates activation-induced cell death of brain microglia. J. Pharmacol. Exp. Ther. 2003, 305, 638-645.
108. Aschner, M. Astrocytes as mediators of immune and inflammatory responses in the CNS. Neurotoxicology 1998, 19, 269-281.
109. Stollg, G.; Jander, S. The role of microglia and macrophages in the pathophysiology of the CNS. Prog. Neurobiol. 1999, 55, 233-247.
110. Becher, B.; Prat, A.; Antel, J.P. Brain-immune connection: immuno-regulatory properties of CNS-resident cells. Glia 2000, 29, 293-304.
111. Lai, M.Y.; Chen, C.C.; Hou, Y.C.; Hsiu, S.L.; Chao, P.D. Analysis and comparison of baicalin, baicalein and wogonin contents in traditional decoctions and commercial extracts of Scutellariae radix. J. Food Drug Anal. 2001, 9, 145-149.
112. Hamada, H.; Hiramatsu, M.; Edamatsu, R.; Mori, A. Free radical scavenging action of baicalein. Arch. Biochem. Biophys. 1993, 306, 261-266.
113. Gao, D.; Sakurai, K.; Katoh, M.; Chen, J.; Ogiso, T. Inhibition of microsomal lipid peroxidation by baicalein: a possible formation of an iron-baicalein complex. Biochem. Mol. Biol. Int. 1996, 39, 215-225.
114. Gao, D.; Tawa, R.; Masaki, H.; Okano, Y.; Sakurai, H. Protective effects of baicalein against cell damage by reactive oxygen species. Chem. Pharm. Bull. 1998, 46, 1383-1387.
115. Gao, Z.; Huang, K.; Yang, X.; Xu, H. Free radical scavenging and antioxidant activities of flavonoids extracted from the radix of Scutellaria baicalensis Georgi. Biochim. Biophys. Acta 1999, 1472, 643-650.
116. Gao, Z.; Huang, K.; Xu, H. Protective effects flavonoids in the roots of scutellaria baicalensis georgi against hydrogen peroxide-induced oxidative stress in HS-SY5Y cells. Pharmacol. Res. 2001, 43, 173-178.
117. Shieh, D.E.; Liu, L.T.; Lin, C.C. Antioxidant and free radical scavenging effects of baicalein, baicalin and wogonin. Anticancer Res. 2000, 20, 2861-2865.
118. Kim, Y.O.; Leem, K.; Park, J.; Lee, P.; Ahn, D.K.; Lee, B.C.; Park, H.K.; Suk, K.; Kim, S.Y.; Kim, H. Cytoprotective effect of Scutellaria baicalensis in CA1 hippocampal neurons of rats after global cerebral ischemia. J. Ethnopharmacol. 2001, 77, 183-188.
119. Lee, H.; Kim, Y.O.; Kim, H.; Kim, S.Y.; Noh, H.S.; Kang, S.S.; Cho, G.J.; Choi, W.S.; Suk, K. Flavonoid wogonin from medicinal herb is neuroprotective by inhibiting inflammatory activation of microglia. FASEB J. 2003, 17, 1943-1944.
120. Cho, J.; Lee, H.K. Wogonin inhibits excitotoxic and oxidative neuronal damage in primary cultured rat cortical cells. Eur. J. Pharmacol. 2004, 485, 105-110. (Pubitemid 38134403)
121. Son, D.; Lee, P.; Lee, J.; Kim, H.; Kim, S.Y. Neuroprotective effect of wogonin in hippocampal slice culture exposed to oxygen and glucose deprivation. Eur. J. Pharmacol. 2004, 493, 99-102.
122. Kim, H.; Kim, Y.S.; Kim, S.Y.; Suk, K. The plant flavonoid wogonin suppresses death of activated C6 rat glial cells by inhibiting nitric oxide production. Neurosci. Lett. 2001, 309, 67-71.
123. Piao, H.Z.; Jin, S.A.; Chun, H.S.; Lee, J.C.; Kim, W.K. Neuroprotective effect of wogonin: potential roles of inflammatory cytokines. Arch. Pharm. Res. 2004, 27, 930-936.
124. O'Neil, L.A.; Kaltschmidt, C. NF-kappa B: a crucial transcription factor for glial and neuronal cell function. Trends Neurosci. 1997, 20, 252-258.
125. Lebeau, A.; Esclaire, F.; Rostène, W.; Pelaprat, D. Baicalein protects cortical neurons from-amyloid (25-35) induced toxicity. Neuroreport 2001, 12, 2199-2202.
126. Heo, H.J.; Kim, D.O; Choi, S.J; Shin, D.H.; Lee, C.Y. Potent inhibitory effect of flavonoids in Scutellaria baicalensis on amyloid β protein-induced neurotoxicity. J. Agric. Food Chem. 2004, 52, 4128-4132.
127. Zhu, M., Rajamani, S.; Kaylor, J., Han, S., Zhou, F.; Fink, A.L. The flavonoid baicalein inhibits fibrillation of a-synuclein and disaggregates existing fibrils. J. Biol. Chem. 2004, 279, 26846-26857. (Pubitemid 38812518)
128. Akao, T.; Kawabata, K.; Yanagisawa, E.; Ishihara, K.; Mizuhara, Y.; Wakui, Y.; Sakashita, Y.; Kobashi, K. Balicalin, the predominant flavone glucuronide of Scutellariae radix, is absorbed from the rat gastrointestinal tract as the aglycone and restored to its original form. J. Pharm. Pharmacol. 2000, 52, 1563-1568.
129. Tsai, T.H.; Liu, S.C.; Tsai, P.L.; Ho, L.K.; Shum, A.Y.C.; Chen, C.F. The effects of the cyclosporin A, a P-glycoprotein inhibitor, on the pharmacokinetics of baicalein in the rat: a microdialysis study. Br. J. Pharmacol. 2002, 137, 1314-1320.
130. Zhang, L.; Lin, G.; Chang, Q.; Zuo, Z. Role of intestinal first-pass metabolism of baicalein in its absorption process. Pharm. Res. 2005, 22, 1050-1058.
131. Zhang, L.; Lin, G.; Zuo, Z. Involvement of UDP-glucuronosyltransferases in the extensive liver and intestinal first-pass metabolism of flavonoid baicalein. Pharm. Res. 2007, 24, 81-89.
132. Hanumanthachar, J.; Patil, J.; Milind, P. Potential of phytochemicals in management of cognitive disorders - An update. Phcog. Rev. 2008, 2, 54-60.
133. Kapoor, L.D. CRC Handbook of Ayurvedic Medicinal Plants; CRC Press: Boca Raton, FL; USA, 1990.
134. Singh, R.H.; Narsimhamurthy, K.; Singh, G. Neuronutrient impact of Ayurvedic Rasayana therapy in brain aging. Biogerontology 2008, 9, 369-374.
135. Strimpakos, A.S.; Sharma, R.A. Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials. Antioxid. Redox Signal. 2008, 10, 511-545.
136. Goel, A.; Jhurani, S.; Aggarwal, B.B. Multi-targeted therapy by curcumin: how spicy is it? Mol. Nutr. Food Res. 2008, 52, 1010-1030.
137. Goel, A.; Kunnumakkara, A.B.; Aggarwal, B.B. Curcumin as "Curecumin": from kitchen to clinic. Biochem. Pharmacol. 2008, 75, 787-809.
138. Ganguli, M.; Chandra, V.; Kamboh, M.I.; Johnston, J.M.; Dodge, H.H.; Thelma, B.K.; Juyal, R.C.; Pandav, R.; Belle, S.H.; DeKosky, S.T. Apolipoprotein E polymorphism and Alzheimer disease: the indo-US cross-national dementia study. Arch. Neurol. 2000, 57, 824-830.
139. Lim, G.P.; Chu, T.; Yang, F.; Beech, W.; Frautschy, S.A.; Cole, G.M. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J. Neurosci. 2001, 21, 8370-8377.
140. Kim, D.S.; Park, S.Y.; Kim, J.K. Curcuminoids from Curcuma longa L. (Zingiberaceae) that protect PC12 rat pheochromocytoma and normal human umbilical vein endothelial cells from betaA(1-42) insult. Neurosci. Lett. 2001, 303, 57-61.
141. Ono, K.; Hasegawa, K.; Naiki, H.; Yamada, M. Curcumin has potent anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro. J. Neurosci. Res. 2004, 75, 742-750.
142. Kim, H.; Park, B.S.; Lee, K.G.; Choi, C.Y.; Jang, S.S.; Kim, Y.H.; Lee, S.E. Effects of naturally occurring compounds on fibril formation and oxidative stress of-amyloid. J. Agric. Food Chem. 2005, 53, 8537-8541.
143. Ringman, J.M.; Frautschy, S.A.; Cole, G.M.; Masterman, D.L.; Cummings, J.L. A potential role of the curry spice in Alzheimer's disease. Curr. Alzheimer Res. 2005, 2, 131-136.
144. Yang, F.; Lim, G.P.; Begum, A.N.; Ubeda, O.J.; Simmons, M.R.; Ambegaokar, S.S.; Chen, P.P.; Kayed, R.; Glabe, C.G.; Frautschy, S.A.; Cole, G.M. Curcumin inhibits formation of amyloid β oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J. Biol. Chem. 2005, 280, 5892-5901.
145. Baum, L.; Ng, A. Curcumin interaction with copper and iron suggests one possible mechanism of action in Alzheimer's disease animal models. J. Alzheimers Dis. 2004, 6, 367-377.
146. Cole, G.M.; Morihara, T.; Lim, G.P.; Yang, F.; Begum, A.; Frautschy, S.A. NSAID and antioxidant prevention of Alzheimer's disease: lessons from in vitro and animal models. Ann. NY Acad. Sci. 2004, 1035, 68-84.
147. Aggarwal, B.B.; Harikumar, K.B. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int. J. Biochem. Cell Biol. 2008, 41, 40-59.
148. Zhang, L.J.; Wu, C.F.; Meng, X.L.; Yuan, D.; Cai, X.D.; Wang, Q.L. Comparison of inhibitory potency of three different curcuminoid pigments on nitric oxide and tumor necrosis factor production of rat primary microglia induced by lipopolysaccharide. Neurosci. Lett. 2008, 447, 48-53.
149. Wang, Q.; Sun, A.Y.; Simonyi, A.; Jensen, M.D.; Shelat, P.B.; Rottinghaus, G.E.; MacDonald, R.S.; Miller, D.K.; Lubah, D.E.; Weisman, G.A.; Sun, G.Y. Neuroprotective mechanisms of curcumin against cerebral ischemia-induced neuronal apoptosis and behavioral deficits. J. Neurosci. Res. 2005, 52, 138-148.
150. Hansen, J.M. Agriculture in the prehistoric Aegean: data versus speculation. Am. J. Archaeol. 1988, 92, 39-52.
151. Simopoulos, A.P. The Mediterranean diets: what is so special about the diet of Greece? The scientific evidence. J. Nutr. 2001, 131, S3065-S3073.
152. La Vecchia, C.; Bosetti, C. Diet and cancer risk in Mediterranean countries. Hungar. Med. J. 2007, 1, 13-23.
153. Trichopoulou, A.; Lagiou, P.; Kuper, H.; Trichopoulos, D. Cancer and Mediterranean dietary traditions. Cancer Epidemiol. Biomarkers Prev. 2000, 9, 869-873.
154. Visioli, F.; Grande, S.; Bogani, P.; Galli, C. The role of antioxidant in the Mediterranean diets: focus on cancer. Eur. J. Cancer Prev. 2004, 13, 337-343.
155. Johnson, H. Vintage: the Story of Wine; Simon & Schuster: New York, NY, USA, 1989; pp. 35-46.
156. Phillips R. A Short History of Wine; HarperCollins: London UK, 2000; pp. 57-63
157. Iriti, M.; Faoro, F. Grape phytochemicals: a bouquet of old and new nutraceuticals for human health. Med. Hypotheses 2006, 67, 833-838.
158. Pervaiz, S. Resveratrol: from grapevines to mammalian biology. FASEB J. 2003, 17, 1975-1985.
159. Iriti, M.; Faoro, F. Bioactivity of grape chemicals for human health. Nat. Prod. Commun. 2009, 4, 611-634.
160. Pinder, R.M. Does wine prevent dementia? Int. J. Wine Res. 2009, 1, 41-52.
161. Peters, R.; Peters, J.; Warner, J.; Beckett, N.; Bulpitt, C. Alcohol, dementia and cognitive decline in the elderly: a systematic review. Age Ageing 2008, 37, 505-512.
162. Klatsky, A.L. Moderate drinking reduced risk of heart disease. Alcohol Res. Health 1999, 23, 15-23.
163. Klatsky, A.L.; Friedman, G.D.; Armstrong, M.A.; Kipp, H. Wine, liquor, beer, and mortality. Am. J. Epidemiol. 2003, 155, 585-595.
164. Charness, M.E. Brain lesions in alcoholics. Alcohol Clin. Exp. Res. 1993, 17, 2-11.
165. Truelsen, T.; Granbsek, M.; Schnohr, P.; Boysen, G. Intake of beer, wine and spirits and risk of stroke. The Copenhagen city heart study. Stroke 1998, 29, 2467-2472.
166. Djousse, L.; Curtis Ellison, R.; Beiser, A.; Scaramucci, A.; D'Agostino, R.B.; Wolf, P.A. Alcohol consumption and risk of ischemic stroke. The Framingham study. Stroke 2002, 33, 907-912.
167. Malarcher, A.M.; Giles, W.H.; Croft, J.B.; Wozniak, M.A.; Wityk, R.J.; Stolley, P.D.; Stern, B.J.; Sloan, M.A.; Sherwin, R.; Price, T.R.; Macko, R.F.; Johnson, C.J.; Earley, C.J.; Buchholz, D.W.; Kittner, S.J. Alcohol intake, type of beverage and risk of cerebral infarction in young women. Stroke 2001, 32, 77-83.
168. Grønbaek, M.; Becker, U.; Johansen, D.; Gottschau, A.; Schnohr, P.; Hein, H.O.; Jensen, G.; Sørensen, T.I.A. Type of alcohol consumed and mortality from all causes, coronary heart disease, and cancer. Ann. Intern. Med. 2000, 133, 411-419.
169. Grønbaek M. Alcohol/disease risk and beneficial effects. In Encyclopaedia of Human Nutrition; Caballero B., Ed.; Elsevier: Amsterdam, The Netherland, 2006; pp. 57-62
170. Conte, A.; Pellegrini, S.; Tagliazucchi, D. Synergistic protection of PC12 cells from β-amyloid toxicity by reveratrol and catechin. Brain Res. Bull. 2003, 62, 29-38.
171. Ono, K.; Yoshiike, Y.; Takashima, A.; Hasegawa, K.; Naiki, H.; Yamada, M. Potent antiamyloidogenic and fibril-destabilizing effects of polyphenols in vitro: implications for the prevention and therapeutics of Alzheimer's disease. J. Neurochem. 2003, 87, 172-181.
172. Savaskan, E.; Olivieri, G.; Meier, E.; Seifritz, E.; Wirz-Justice, A.; Muller-Spahn, F. Red wine ingredient resveratrol protects from β-amyloid neurotoxicity. Gerontology 2003, 49, 380-383.
173. Porat, Y.; Abramowitz, A.; Gazit, E. Inhibition of amyloid fibril formation by polyphenols: structural similarity and aromatic interactions as a common inhibition mechanism. Chem. Biol. Drug Des. 2006, 67, 27-37.
174. Rivière, C.; Richard, T.; Vitrac, X.; Mérillon, J.M.; Valls, J.; Monti, J.P. New polyphenols active on-amyloid aggregation. Bioorg. Medic. Chem. Lett. 2008, 18, 828,831.
175. Blanchet, J.; Longpré, F.; Bureau, G.; Morisette, M.; DiPaolo, T.; Bronchti, G.; Martinoli, M.G. Resveratrol, a red wine polyphenol, protects dopaminergic neurons in MPTP-treated mice. Progr. Neuro-Psychopharmacol. Biol. Psych. 2008, 32, 1243-1250.
176. Marambaud, P.; Zhao, H.; Davies, P. Resveratrol promotes clearance of Alzheimer's disease amyloid-β peptides. J. Biol. Chem. 2005, 280, 37377-37382.
177. Bastianetto, S.; Zheng, W.H.; Quirion, R. Neuroprotective abilities of resveratrol and other red wine constituents against nitric oxide toxicity in cultured hippocampal neurons. Br. J. Pharmacol. 2000, 131, 711-720.
178. Wang, J.; Ho, L.; Zhao, W.; Seror, I.; Humala, N.; Dickstein, D.L.; Thiyagarajan, M.; Percival, S.S.; Talcott, S.T.; Pasinetti, G.M. Moderate consumption of Cabernet Sauvignon attenuates A neuropathology in a mouse model of Alzheimer's diseases. FASEB J. 2006, 20, 2313-2320.
179. Wang, J.; Ho, L.; Zhao, W.; Ono, K.; Rosensweig, C.; Chen, L.; Humala, N.; Teplow, D.B.; Pasinetti, G.M. Grape-derived polyphenolics prevent A oligomerization and attenuate cognitive deterioration in a mouse model of Alzheimer's disease. J. Neurosci. 2008, 28, 6388-6392.
180. Howitz, K.T.; Bitterman, K.J.; Cohen, H.Y.; Lamming, D.W.; Lavu, S.; Wood, J.G.; Zipkin, R.E.; Chung, P.; Kisielewski, A.; Zhang, L.L.; Scherer, B.; Sinclair, D.A. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003, 425, 191-196.
181. Wood, J.G.; Rogina, B.; Lavu, S.; Howitz, K.; Helfand, S.L.; Tartar, M.; Sinclair, D.A. Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature 2004, 430, 686-689.
182. Bordone, L.; Guarente, L. Calorie restriction, SIRT1 and metabolism: understanding longevity. Nature Rev. Mol. Cell Biol. 2005, 6, 298-305. (Pubitemid 40516896)
183. Chen, D.; Guarente, L. SIR2: a potential target for calorie restriction mimetics. Trends Mol. Med. 2006, 13, 64-71.
184. Haigis, M.C.; Guarente, L.P. Mammalian sirtuins-emerging roles in physiology, aging and calorie restriction. Genes Develop. 2006, 20, 2913-2921.
185. Outeiro, T.F.; Marques, O.; Kazantsev, A. Therapeutic role of sirtuins in neurodegenerative disease. Biochim. Biophys. Acta 2008, 1752, 363-369.
186. Michan, S.; Sinclair, D. Sirtuins in mammals: insights into their biological function. Biochem. J. 2007, 404, 1-13.
187. Yamamoto, H.; Schoonjans, K.; Auwerx, J. Sirtuin functions in health and disease. Mol. Endocrinol. 2007, 21, 1745-1755.
188. Anekonda, T.S. Resveratrol-a boon for Alzheimer's disease? Brain Res. Rev. 2006, 52, 316-326.
189. Anekonda, T.S.; Reddy, P.H. Neuronal protection by sirtuins in Alzheimer's disease. J. Neurochem. 2006, 96, 305-313.
190. Porcu, M.; Chiarugi, A. The emerging therapeutic potential of sirtuin-interacting drugs: from cell death to lifespan extension. Trends Pharmacol. Sci. 2005, 26, 94-103.
191. Lavu, S.; Boss, O.; Elliott, P.J.; Lambert, P.D. Sirtuins-novel therapeutic targets to treat age-associated diseases. Nature Rev. Drug Discov. 2008, 7, 841-853.
192. Tapsell, L.C.; Hemphill, I.; Cobiac, L.; Patch, C.S.; Sullivan, D.R.; Fenech, M.; Roodenrys, S.; Keogh, J.B.; Clifton, P.M.; Williams, P.G.; Fazio, V.A.; Inge, K.E. Health benefits of herbs and spices: The past, the present, the future. Med. J. Aust. 2006, 155, S4-S24.
193. Ninfali, P.; Mea, G.; Giorgini, S.; Rocchi, M.; Bacchiocca, M. Antioxidant capacity of vegetables, spices, and dressings relevant to nutrition. Brit. J. Nutr. 2005, 93, 257-266.
194. dos Santos-Neto, L.L.; de Vilhena Toledo, M.A.; Medeiros-Souza, P.; de Souza, G.A. The use of herbal medicine in Alzheimer's disease-A systematic review. Evid.-Based Complement. Altern. Med. 2006, 3, 441-445.
195. Bozin, B.; Mika-Dukic, N.; Samojlik, I.; Jovin, E. Antimicrobial and antioxidant properties of rosemary and sage (Rosmarinus officinalis L. and Salvia officinalis L., Lamiaceae) essential oils. J. Agric. Food. Chem. 2007, 55, 7879-7885.
196. Cheung, S.; Tai, J. Anti-proliferative and antioxidant properties of rosemary Rosmarinus officinalis. Oncol. Rep. 2007, 17, 1525-1531.
197. Imanshahidi, M.; Hosseinzadeh, H. The pharmacological effects of Salvia species on the central nervous system. Phytother. Res. 2006, 20, 427-437.
198. Perry, N.S.L.; Houghton, P.J.; Theobald, A.; Jenner, P.; Perry, E.K. In-vitro inhibition of erythrocyte acetylcholinesterase by Salvia lavandulaefolia essential oil and constituent terpenes. J. Pharm. Pharmacol. 2000, 53, 1347-1356.
199. 199. Tildesley, N.T.J.; Kennedy, D.O.; Perry, E.K.; Ballard, C.G.; Savelev, S.; Wesnes, K.A.; Scholey, A.B. Salvia lavandulaefolia (Spanish Sage) enhances memory in healthy young volunteers. Biochem. Pharmacol. Behav. 2003, 75, 669-674.
200. Savelev, S.U.; Okello, E.; Perry, N.S.L.; Wilkins, R.M.; Perry, E. Synergistic and antagonistic interactions of anticholinesterase terpenoids in Salvia lavandulaefolia essential oil. Biochem. Pharmacol. Behav. 2003, 75, 661-668.
201. Savelev, S.U.; Okello, E.J.; Perry, E.K. Butyryl-and acetyl- cholinesterase inhibitory activities in essential oils of Salvia species and their constituents. Phytother. Res. 2004, 15, 315-324.
202. Tildesley, N.T.J.; Kennedy, D.O.; Perry, E.K.; Ballard, C.G.; Wesnes, K.A.; Scholey, A.B. Positive modulation of mood and cognitive performance following administration of acute doses of Salvia lavandulaefolia essential oil to healthy young volunteers. Physiol. Behav. 2005, 53, 699-709.
203. Moretti, M.D.L.; Peana, A.T.; Satta, M. A study on anti-inflammatory and peripheral analgesic action of Salvia sclarea oil and its main components. J. Essent. Oil Res. 1997, 9, 199-204.
204. Zupkó, I.; Hohmann, J.; Rédei, D.; Falkay, G.; Janicsák, G.; Máthé, I. Antioxidant activity of leaves of Salvia species in enzyme-dependent and enzyme-independent systems of lipid peroxidation and their phenolic constituents. Planta Med. 2001, 67, 366-368.
205. Perry, N.S.L.; Bollen, C.; Perry, E.K.; Ballard, C. Salvia for dementia therapy: review of pharmacological activity and pilot tolerability clinical trial. Pharmacol. Biochem. Behav. 2003, 75, 651-659.
206. Akhondzadeh, S.; Noroozian, M.; Mohammadi, M.; Ohadinia, S.; Jamshidi, A.H.; Khani, M. Salvia officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomized and placebo-controlled trial. J. Clin. Pharm. Ther. 2003, 25, 53-59. (Pubitemid 36313176)
207. Lundsberg L.S. Caffeine consumption. In Caffeine; Spiller, G.A., Ed.; CRC Press: Boca Raton, FL, USA, 1998; pp. 199-224
208. Cauli, O.; Morelli, M. Caffeine and the dopaminergic system. Behav. Pharmacol. 2005, 16, 63-77.
209. Gu, L.; Gonzalez, F.J.; Kalow, W.; Tang, B.K. Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1. Pharmacogenet. Genomics 1992, 2, 73-77.
210. Maia, L.; de Mendonca, A. Does caffeine intake protect from Alzheimer's disease? Eur. J. Neurol. 2002, 9, 377-382.
211. Barranco Quintana, J.L.; Allam, M.F.; Serrano Del Castillo, A.R.; Fernandez-Crehuet Navajas, R. Alzheimer's disease and coffee: a quantitative review. Neurol. Res. 2007, 29, 91-95.
212. Ascherio, A.; Weisskopf, M.G.; O'Reilly, E.J. Coffee consumption, gender, and Parkinson's disease mortality in the cancer prevention study II cohort: the modifying effects of estrogen. Am. J. Epidemiol. 2004, 160, 977-984.
213. Ascherio, A.; Zhang, S.M.; Hernan, M.A. Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann. Neurol. 2001, 50, 56-63.
214. Ascherio, A.; Chen, H. Caffeinated clues from epidemiology of Parkinson's disease. Neurology 2003, 61, S51-S54.
215. al'Absi M.; Lovallo W.R. Caffeine effects on the human stress axis. In Coffee, tea, chocolate and the brain; Nehlig, A., Ed.; CRC Press: Boca Raton,FL, USA, 2004; pp. 113-131.
216. Khokhar, S.; Magnusdottir, S.G. Total phenol, catechin, and caffeine contents of teas commonly consumed in the United kingdom. J. Agric. Food Chem. 2002, 50, 565-570.
217. Perva-Uzunalic, A.; Skerget, M.; Knez, Z.; Weinreich, B.; Otto, F.; Grüner, S. Extraction of acive ingredients from green tea (Camelia sinensis): Extraction efficiency of major catechins and caffeine. Food Chem., 2006, 96, 597-605.
218. Kuriyama, S.; Hozawa; A.; Ohmori, K.; Shimazu, T.; Matsui, T.; Ebihara, S.; Awata, S.; Nagatomi R.; Arai, H.; Tsuji, I. Green tea consumption and cognitive function: a cross-sectional study from the Tsurugaya Project 1. Am. J. Clin. Nutr. 2006, 83, 355-361.
219. Nagao, T.; Komine, Y.; Soga, S.; Meguro, S.; Hase, T.; Tanaka, Y.; Tokimitsu, I. Ingestion of a tea rich in catechins leads to a reduction in body fat and malondialdehyde-modified LDL in men. Am. J. Clin. Nutr. 2005, 81, 122-129.
220. Sasazuki, S.; Kodama, H. Relation between green tea consumption and the severity of coronary atherosclerosis among Japanese men and women. Ann. Epidemiol. 2000, 10, 401-408.
221. Chen, D.; Daniel, K.G.; Kuhn, D.J.; Kazi, A.; Bhuiyan, M.; Li, L.; Wang, Z.; Wan, S.B.; Lam, W.H.; Chan, T.H.; Dou, Q.P. Green tea and tea polyphenols in cancer prevention. Front Biosci. 2004, 9, 2618-2631.
222. Coimbra, S.; Castro, E.; Rocha-Pereira, P.; Rebelo, I.; Rocha, S.; Santos-Silva, A. The effect of green tea in oxidative stress. Clin. Nutr.2006, 25,790-796.
223. Huh, S.W.; Bae, S.M.; Kim, Y.W.; Lee, J.M.; Namkoong, S.E.; Lee, I.P.; Kim, S.H.; Kim, C.K.; Ahn, W.S. Anticancer effects of (-)-epigallocatechin-3- gallate on ovarian carcinoma cell lines. Gynecol Oncol. 2004, 94, 760-768.
224. Hussain. T.; Gupta, S.; Adhami, V.M.; Mukhtar, H. Green tea constituent epigallocatechin-3-gallate selectively inhibits COX-2 without affecting COX-1 expression in human prostate carcinoma cells. Int. J. Cancer. 2005, 113, 660-669.
225. Larsson, S.C.; Wolk, A. Tea consumption and ovarian cancer risk in a population-based cohort. Arch. Intern. Med. 2005, 165, 2683-2686. (Pubitemid 41785069)
226. Muraki, S.; Yamamoto, S.; Oka, H.; Yoshimura, N.; Kawaguchi, H.; Orimo, H.; Nakamura, K. Green tea drinking is associated with increased bonemineral density in elderly women. In Study P187SA, Proceedings of the International Osteoporosis Foundation World Congress on Osteoporosis, Toronto, Canada, June 5, 2006.
227. Sakanaka, S.; Okada, Y. Inhibitory effects of green tea polyphenols on the production of a virulence factor of the periodontal-disease-causing anaerobic bacterium Porphyromonas gingivalis. J. Agric. Food Chem. 2004, 52, 1688-1692.
228. Sano, J.; Inami, S.; Seimiya, K.; Ohba, T.; Sakai, S.; Takano, T.; Mizuno K. Effects of green tea intake on the development of coronary artery disease. Circ. J. 2004, 8, 665-670.
229. Siddiqui, I.A.; Afaq, F.; Adhami, V.M.; Ahmad, N.; Mukhtar, H. Antioxidants of the beverage tea in promotion of human health. Antioxid. Redox Signal. 2004, 6, 571-582.
230. Song, J.M.; Lee, K.H.; Seong, B.L. Antiviral effect of catechins in green tea on influenza virus. Antiviral Res. 2005, 68, 66-74.
231. Mandel, S.; Youdim, M.B. Catechin polyphenols: neurodegeneration and neuroprotection in neurodegenerative diseases. Free Radic. Biol. Med. 2004, 37, 304-317.
232. Reznichenko, L., Amit, T., Zheng, H.; Avramovich-Tirosh, Y.; Youdim, M.B., Weinreb, O.; Mandel, S. Reduction of iron-regulated amyloid precursor protein and beta-amyloid peptide by (-)-epigallocatechin-3-gallate in cell cultures: implications for iron chelation in Alzheimer's disease. J. Neurochem. 2006, 97, 527-536.
233. Weinreb, O.; Mandel, S.; Amit, T.; Youdim, M.B. Neurological mechanisms of green tea polyphenols in Alzheimer's and Parkinson's diseases. J. Nutr. Biochem. 2004, 15, 506-516.
234. Haque, A.M.; Hashimoto, M.; Katakura, M.; Tanabe, Y.; Hara, Y.; Shido, O. Long-term administration of green tea catechins improves spatial cognition learning ability in rats. J. Nutr. 2006, 136, 1043-1047.
235. Gray, J. Caffeine, coffee and health. Nutr. Food Sci. 1998, 6, 314-319.
236. Iriti, M.; Faoro, F. Chemical diversity and defence metabolism: how plants cope with pathogens and ozone pollution. Int. J. Mol. Sci. 2009, 10, 3371-3399.
237. Schmitt-Schillig, S.; Schaffer, S.; Weber, C.C.; Eckert, G.P.; Müller, W.E. Flavonoids and the aging brain. J. Physiol. Pharmacol. 2005, 56, 23-36.
238. Peng, H.W.; Cheng, F.C.; Huang, Y.T.; Chen, C.F.; Tsai, T.H. Determination of naringinin and its glucoronide conjugate in rat plasma and brain tissue by high-performance liquid chromatography. J. Chromat. 1998, 714, 369-374.
239. Tsai, T.H.; Chen, Y.F. Determination of unbound hesperetin in rat blood and brain by microdialysis coupled to microbore liquid chromatography. J. Food Drug Anal. 2000, 5, 331-336.
240. Abd El Mohsen, M.M.; Kuhnle, G.; Rechner, A.R. Uptake and metabolism of epicatechin and its access to the brain after oral ingestion. Free Rad. Biol. Med. 2002, 33, 1693-1702.
241. Youdim, K.A.; Dobbie, M.S.; Kuhnle, G. Interaction between flavonoids and the blood-brain barrier: in vitro studies. J. Neurochem. 2003, 55, 180-192.
242. Youdim, K.A.; Shukitt-Hale, B.; Joseph, J.A. Flavonoids and the brain: interactions at the blood-brain barrier and their physiological effects on the central nervous systems. Free Rad. Biol. Med. 2004, 37, 1683-1693.
243. Tamatani, M.; Che, Y.H.; Matsuzaki, H.; Ogawa, S.; Okado, H.; Miyake, S.; Mizuno, T.; Tohyama, M. Tumor necrosis factor induces Bcl-2 and Bcl-x expression through NFkB activation in primary hippocampal neurons. J. Biol. Chem. 1999, 274, 8531-8538.
244. Manach, C.; Scalbert, A.; Morand, C.; Remesy, C.; Jimenez, L. Polyphenols-food sources and bioavailability. Am. J. Clin. Nutr. 2004, 79, 727-747.
245. 245. Manach, C.; Williamson, G.; Morand, C.; Scalbert, A.; Remesy, C. Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies Am. J. Clin. Nutr. 2005, 51, 230S-242S.
246. Williamson, G.; Manach, C. Bioavailability and bioefficacy of polyphenols in humans. II. Review of 93 intervention studies. Am. J. Clin. Nutr. 2005, 51, 243S-255S.
247. Gilgun-Sherki, Y.; Melamed, E.; Offen, D. Oxidative stress induced-neurodegenerative disease: the need for antioxidants that penetrate the blood brain barrier. Neuropharmacology 2001, 40, 959-975.
248. Dajas, F.; Rivera-Megret, F.; Blasina, F.; Arredondo, F.; Abin-Carriquiry, J.A.; Costa, G.; Echeverry, C.; Lafon, L.; Heizen, H.; Ferreira, M.; Morquio, A. Neuroprotection by flavonoids. Braz. J. Med. Biol. Res. 2003, 36, 1613-1620.
249. Ramassamy, C. Emerging role of polyphenolic compounds in the treatment of neurodegenerative diseases: a review of their intracellular targets. Eur. J. Pharmacol. 2006, 545, 51-64.